Clearance Summary
Afinion HbA1c Dx received FDA 510(k) clearance under submission number K180296, sponsored by Alere Technologies AS. The device was reviewed via the Traditional premarket notification pathway and assigned to the Clinical Chemistry review panel. The statutory decision date of record is 2018-05-07.
- Submission: K180296
- Applicant / Sponsor: Alere Technologies AS
- Clearance pathway: Traditional
- Review panel: Clinical Chemistry
- Device class: Class II
- Regulation citation: 21 CFR 862.1373
- Decision date: 2018-05-07
Classification & Regulation
This clearance is catalogued under FDA product code PDJ and 21 CFR 862.1373, within the Clinical Chemistry review panel as a Class II device.